Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

نویسندگان

  • Rickard E. Malmström
  • Brian B. Godman
  • Eduard Diogene
  • Christoph Baumgärtel
  • Marion Bennie
  • Iain Bishop
  • Anna Brzezinska
  • Anna Bucsics
  • Stephen Campbell
  • Alessandra Ferrario
  • Alexander E. Finlayson
  • Jurij Fürst
  • Kristina Garuoliene
  • Miguel Gomes
  • Iñaki Gutiérrez-Ibarluzea
  • Alan Haycox
  • Krystyna Hviding
  • Harald Herholz
  • Mikael Hoffmann
  • Saira Jan
  • Jan Jones
  • Roberta Joppi
  • Marija Kalaba
  • Christina Kvalheim
  • Ott Laius
  • Irene Langner
  • Julie Lonsdale
  • Sven-Äke Lööv
  • Kamila Malinowska
  • Laura McCullagh
  • Ken Paterson
  • Vanda Markovic-Pekovic
  • Andrew Martin
  • Jutta Piessnegger
  • Gisbert Selke
  • Catherine Sermet
  • Steven Simoens
  • Cankat Tulunay
  • Dominik Tomek
  • Luka Vončina
  • Vera Vlahovic-Palcevski
  • Janet Wale
  • Michael Wilcock
  • Magdalena Wladysiuk
  • Menno van Woerkom
  • Corrine Zara
  • Lars L. Gustafsson
چکیده

BACKGROUND There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have shown dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. There are also issues with potentially re-designing anticoagulant services. This has resulted in activities across countries to better manage its use. OBJECTIVE To (i) review authority activities in over 30 countries and regions, (ii) use the findings to develop new models to better manage the entry of new drugs, and (iii) review the implications for all major stakeholder groups. METHODOLOGY Descriptive review and appraisal of activities regarding dabigatran and the development of guidance for groups through an iterative process. RESULTS There has been a plethora of activities among authorities to manage the prescribing of dabigatran including extensive pre-launch activities, risk sharing arrangements, prescribing restrictions, and monitoring of prescribing post-launch. Reimbursement has been denied in some countries due to concerns with its budget impact and/or excessive bleeding. Development of a new model and future guidance is proposed to better manage the entry of new drugs, centering on three pillars of pre-, peri-, and post-launch activities. CONCLUSION Models for introducing new drugs are essential to optimize their prescribing especially where there are concerns. Without such models, new drugs may be withdrawn prematurely and/or struggle for funding.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

BACKGROUND There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the el...

متن کامل

Conservative Management of Dabigatran Overdose: Case Report and Review of Literature

Background: Direct thrombin inhibitors and factor Xa inhibitors are gaining popularity as alternatives to warfarin for patients requiring anticoagulation. Toxicity due to these medications is difficult to manage because overdose experience is very limited and there is no clear guidance on when or whether to use antidote in this setting. Case Presentation: A 50-year-old man with normal renal fu...

متن کامل

Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin

  Atrial fibrillation (AF) is associated with inflammatory and hypercoagulability state. Previous studies evaluated the safety and efficacy of dabigatran and warfarin in prevention of thrombothic complications. This study was intended to assess the influence of these drugs on hemostatic and inflammatory markers among patient underwent pulmonary vein ablation.   A total of 100 patients with AF w...

متن کامل

Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin

  Atrial fibrillation (AF) is associated with inflammatory and hypercoagulability state. Previous studies evaluated the safety and efficacy of dabigatran and warfarin in prevention of thrombothic complications. This study was intended to assess the influence of these drugs on hemostatic and inflammatory markers among patient underwent pulmonary vein ablation.   A total of 100 patients with AF w...

متن کامل

Modeling a semantic recommender system for medical prescriptions and drug interaction detection

Introduction: The administration of appropriate drugs to patients is one of the most important processes of treatment and requires careful decision-making based-on the current conditions of the patient and its history and symptoms. In many cases, patients may require more than one drug, or in addition to having a previous illness and receiving the drug, they need new drugs for the new illness, ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 4  شماره 

صفحات  -

تاریخ انتشار 2013